{"id":"W2138297714","doi":"10.1056/nejmoa050753","title":"Erlotinib in Previously Treated Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5451,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; Hotel Dieu Shaver Health and Rehabilitation Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Erlotinib Hydrochloride; Chemotherapy; Randomization; Placebo; Performance status; Oncology; Surgery; Epidermal growth factor receptor; Gastroenterology; Cancer; Randomized controlled trial; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}